-
Study aim
-
Determining the Effect of Glutamine Supplementation on Biomarkers of Cardiomyopathy, Body Composition Changes, and Quality of Life in Breast Cancer Patients Undergoing Chemotherapy: A Clinical Trial Study.
-
Design
-
A double-blind randomized controlled trial, phase 3 with 46 patients, randomization with RAND excel function
-
Settings and conduct
-
Patients visiting the Mehraneh Clinic will be enrolled in the study using a easy sampling method. Patients will be randomly assigned to two groups. The packages containing the supplement and placebo will be coded with the numbers 1 or 2 by an individual not involved in the study, ensuring that both the researcher and the patients remain unaware of the type of supplement received by the participants.
-
Participants/Inclusion and exclusion criteria
-
Adult Women (18 years and older) with Breast Cancer Initiating Chemotherapy Visiting the Mehraneh Charity Association in Zanjan. Exclusion criteria: reporting excessive or insufficient food intake (800-4200 kcal), Body Mass Index (BMI) less than 18.5 or greater than 45, substance abuse or alcohol consumption at least once a week, pregnancy and lactation, CKD, CAD, MI, ESRD, DM, or liver disease.
-
Intervention groups
-
Glutamine supplementation and placebo will be administered for a duration of 8 weeks. A complete blood sample will be collected to assess the serum levels of the targeted biomarkers. Additionally, anthropometric data, demographic questionnaires, quality of life assessments, body composition analyses, and echocardiographic tests will be analyzed and completed before and after the intervention.
-
Main outcome variables
-
Levels of cTnT and CK-MB, anthropometric indices, body composition analysis, echocardiographic tests, and quality of life.